Navigation Links
Takeda to Create Global Centers of Excellence
Date:3/30/2009

Reorganization helps Takeda realize globalization vision

OSAKA, Japan, March 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company's global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.

"Takeda is making meaningful changes in structure and governance through this reorganization and the creation of the CSO, EVP, International Operations, and CAO roles, which we believe will further strengthen our global operations structure," said Yasuchika Hasegawa, President, Takeda Pharmaceutical Company Limited. "Through this new organizational structure, Takeda looks forward to continuing our history of creating and marketing novel pharmaceutical products that meet the needs of patients globally."

Details of the Reorganization

Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will assume the role of Chief Scientific Officer, responsible for global Research, Development, Chemistry Manufacturing and Controls (CMC), and Intellectual Property (IP). The creation of the CSO role provides the opportunity to further enhance product development effectiveness through the integration of research and development. The
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Takeda Receives New Information on Alogliptin (SYR-322) NDA
2. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
3. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
4. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
5. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
6. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
7. Takeda Completes Acquisition of Millennium
8. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
9. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
10. Takeda Announces New U.S. Leadership
11. Takeda submits new drug application for alogliptin (syr-322) in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm ... investor-families have received permanent green cards (I-829 petition approval) from the USCIS through ... is the final step of the EB-5 visa process for immigrant investors to ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin ... the VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the ... Clear. , Formulated with alpha hydroxy acids and natural active ingredients, these ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... information about new patients directly from Practice Perfect to FOTO enabling cost and ... , Steven Presement, President of Practice Perfect, stated "FOTO is ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices ... take a look at the topic of arthritis. There are over 100 different types ... interesting arthritis types and statistics in an effort to shed light on this important ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... retailer of professional hair salons. This highly anticipated partnership between Curly Hair Solutions™ ... Keeper™ Styling Collection. Founder Jonathan Torch and the Curly Hair Solutions™ team could ...
Breaking Medicine News(10 mins):Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:Curly Hair Solutions™ Partners With Trade Secrets 2
... says that a predictive model may be used to predict ... cell anemia is one of the sickle cell disease. A ... the condition where there is anemia and sickle cell hemoglobin ... genes in 1398 patients suffering from sickle cell anemia. The ...
... Bioinformatics (Bangalore) had made a study of the genomic sequence ... as well. ,The IOB analysis showed that the ... chromosomes with 43 novel protein-coding regions and 696 known genes. ... out the detail of pseudogenes on X chromosome. The study ...
... linoleic acid (CLA) by overweight people had showed a reduction in ... ,The study was conducted to analyze the effects of ... effects on body fat mass, lean body mass, bone mineral mass, ... in the triglyceride form. ,The results showed that there was ...
... Schiavo died in the Pinellas Park hospital on Thursday. Terri ... the right-to-die controversy.// She died today 13 days after her ... court judge. ,Terri Schiavo was 26 years when ... from potassium deficiency, due to extreme weight loss. Doctors said ...
... COPD is a lung disease that often results from years ... test measuring // lung hyperinflation can be used to predict ... pulmonary disease (COPD) . ,For the study researchers compared ... to total lung capacity in 689 COPD patients. Results showed ...
... Research Institute and University of Melbourne, Australia have identified ... enzyme called ADAMTS5 destroys the cartilage by degrading the ... inflammations and the severe joint pains that are the ... a condition that not only affects the elderly, but ...
Cached Medicine News:
(Date:9/1/2015)... LAVAL, Quebec , Sept. 1, 2015 /PRNewswire/ ... and TSX: VRX) today announced that its affiliate ... under which Valeant was granted an exclusive license ... Brodalumab is an IL-17 receptor monoclonal antibody in ... psoriatic arthritis. Under the agreement, Valeant will hold ...
(Date:8/31/2015)... 31, 2015  DICOM Grid,  the #1 medical ... was recognized as a semifinalist for a Minnie ... The awards are sponsored by Auntminnie.com, a comprehensive ... the medical imaging industry.  Since 1999, the "Minnies" ... acknowledge the contributions of their peers. Nominations are ...
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
Breaking Medicine Technology:Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9
... an in-line, battery-powered disposable, lightweight and completely ... capable of intravenous application and irrigation warming. ... to help prevent fluid-induced hypothermia. The ... 38°C (100.4°F) 3°C at a flow rate ...
Using the patient's own blood pressure as the driving force, CAVR circulates cold blood through the Level 1 heat exchanger and returns it to the patient at body temperature for rapid core rewarming....
... a ruggedly built, simple to operate fluid warmer ... controlled warming of blood or other fluids being ... by a water reservoir which is heated by ... which is backed up by a thermoswitch. Blood ...
... clinicians., ,Building off the proven technology ... MRI is one of the few MRI ... integrated ventilator. Validated for use the MRI ... magnet), the Aestiva/5 MRI uses the same ...
Medicine Products: